Results from the CLAIM study published online in Lancet Respiratory Medicine on February 21, 2018 show that COPD patients using Novartis’s Ultibro Breezhalerindacaterol/glycopyrronium DPI had significantly decreased lung hyperinflation and improved cardiac function after 14 days compared to placebo.
Ultibro Breezhaler has been approved for the treatment of COPD in Europe since 2013. In the US, where it is marketed as Utibron Neohaler, the inhaler has been approved since 2015. Ultibro Breezhaler is also approved in a number of other countries, including Japan, Canada, and Australia.
The CLAIM study compared once-daily treatment with Ultibro Breezhaler to placebo in 62 patients with moderate-to-very severe COPD. Of the 62 patients, 57 completed both 14-day treatment periods. The primary endpoint was the effect on left ventricular end-diastolic volume after 14 days of treatment, and lung function measures including residual volume, FEV1, and FVC were secondary endpoints.
Novartis Pharmaceuticals Chief Medical Officer and Global Head of Medical Affairs Shreeram Aradhye commented, “Lung hyperinflation is often associated with impaired cardiac function in patients with COPD. The publication of the CLAIM study is important for any COPD patient with signs of lung hyperinflation. For the first time, we demonstrated that treatment with Ultibro Breezhaler can reduce lung hyperinflation and improve cardiac function, breathlessness and health status.”
Read the Novartis press release.
Read the Lancet Respiratory Medicine article.
